Vascular Biogenics Surges for Third Day on Cancer Drug Prospect

  • Company to present data on VB-111 drug on Sept. 27 in Vienna
  • Chardan rated stock a buy on promise of gene therapy drug

Vascular Biogenics Ltd., the Israeli biotechnology company that is developing cancer treatments, rallied for a third day on bets it will show promising results from clinical drug trials at a medical conference in Europe this weekend.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.